Stuart Smith, MD
Family Medicine · Bismarck, NDNPI 1821196577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 711 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 711 payments — averaging $11.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$1K
- Pfizer$921
- AstraZeneca$794
- AbbVie$731
- plus $2K from 28 others
What the payments were for
- Food & beverage$8,245100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 128 | $1,226 |
| Novo Nordisk | 157 | $1,069 |
| Amgen | 89 | $1,043 |
| Pfizer | 88 | $921 |
| AstraZeneca | 10 | $794 |
| AbbVie(2 entities) | 57 | $731 |
| Astellas Pharma US Inc | 26 | $464 |
| Dexcom, Inc. | 15 | $270 |
| Boehringer Ingelheim | 23 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $167 |
| GSK | 24 | $166 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $132 |
| E.r. Squibb & Sons, L.L.C. | 7 | $124 |
| Bayer | 7 | $100 |
| Novartis | 7 | $100 |
| Phathom Pharmaceuticals, Inc. | 8 | $81 |
| Daiichi Sankyo Inc. | 4 | $76 |
| Johnson & Johnson(2 entities) | 6 | $74 |
| Eisai Inc. | 3 | $72 |
| Sanofi-aventis U.S. LLC | 5 | $64 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Merck | 4 | $51 |
| Radius Health, Inc. | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Medtronic | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Abbott | 1 | $17 |
| Ardelyx, Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,245 in reported general payments places this provider in the 95th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $130,698 |
| IngrezzaValbenazine Tosylate | 11 | $95,020 |
| EliquisApixaban | 83 | $47,832 |
| JardianceEmpagliflozin | 45 | $27,485 |
| TrulicityDulaglutide | 16 | $17,417 |
| XareltoRivaroxaban | 25 | $14,462 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $7,103 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,582 |
| VascepaIcosapent Ethyl | 18 | $5,542 |
| Atorvastatin Calcium | 476 | $5,341 |
| Varenicline Tartrate | 13 | $5,057 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $4,861 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,820 |
| Tamsulosin Hcl | 239 | $3,720 |
| Novolog FlexpenInsulin Aspart | 19 | $3,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,069 | $130,698129 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $14 | $95,02011 claims |
| PfizerEliquis, Premarin | $921 | $50,55295 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $191 | $33,06756 claims |
| Lilly USA, LLCTrulicity | $1,226 | $17,41716 claims |
| Johnson & JohnsonXarelto | $74 | $14,46225 claims |
| GSKIncruse Ellipta | $166 | $3,82011 claims |
| AbbVieSynthroid | $731 | $1,04419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Bismarck
- Jacqueline QuisnoBismarck$19K
- Jeffrey SmithBismarck$15K
- David PengillyBismarck$8K
- Biron BakerBismarck$8K
- Michelle TincherBismarck$7K
- Kevin LongieBismarck$6K
- Kelly LongieBismarck$5K
- Sherry SteinBismarck$5K
- David FieldBismarck$5K
- Brandon PriceBismarck$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.